

## **Amendment no. 1**

**No.: - BPPI/DRUG/RC-163/2021**

**Dated: 07/04/2021**

**Subject: - Tender No. BPPI/DRUG/RC-163/2021 dated 18/03/2021 for supply of drug/medicine to Bureau of Pharma Public Sector undertakings of India (BPPI).**

**Reference: - Pre-Bid meeting held on 26/03/2021 at 11:00 AM in the premises of BPPI.**

Bureau of Pharma PSUs of India (BPPI) has invited e-Bids from the interested parties for “e- Tender for Supply of Drug/Medicine for the year 2021- 2023”, vide Notice Inviting Tender No.- **BPPI/DRUG/RC-163/2021**. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website of Central Public Procurement Portal; [www.eprocure.gov.in](http://www.eprocure.gov.in) and BPPI Website; [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in) .

After considering the suggestions/ queries received from the prospective bidders on or before Pre-Bid meeting, the clarifications/ amendments with regard to the tender document and specification of the tendered items have been made as per below Annexure-A and Annexure-B respectively. All other technical specifications, terms and conditions along with the tender schedule as mentioned in tender document shall remain unchanged.

The following amendment in Tender Document is hereby authorized: -

### **Annexure- A**

<b>Sl. No.</b>	<b>Tender Clause/Reference</b>	<b>Query/Suggestion</b>	<b>Clarification/ Amendment</b>
<b>1</b>	<b>Clause no. 3. I. ELIGIBILITY CRITERIA (TECHNICAL BID - COVER “A”):</b>	One of the bidders has requested to clarify the turnover criteria highlighting the tender requirement of average annual turnover for any three of the last four consecutive financial years not less than 25 Crores (Twenty-Five crore). The bidder has also mentioned that they fall under MSME category.	The bidders must have average annual turnover not less than 25 Crores (Twenty-Five crore) for any three of the last four consecutive financial years.  Further turnover has not been relaxed.
<b>2</b>	<b>Sub Clause no. (e) to 3. D. ELIGIBILITY CRITERIA (TECHNICAL BID -COVER “A”) and Para V of Annexure IV</b>	One of bidder has requested to remove specific line i.e., “Bidder must have Market Standing Certificate (in India) of minimum two batches of quoted product in last three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product” saying the same line is being declared by the bidder in Annexure IV. They also mentioned that the Drug Controller has their own format to issue Market Standing Certificate which specifies that the bidder is manufacturing, and marketing quoted product from last 3 years.	The bidder may submit Market Standing Certificate issued in Drug Controllers for each quoted product confirming that they are manufacturing the drug since last three years.

3	Annexure -XII Clause 18 (M) & BOQ	Bidders has requested to accept Drug/medicines either in USP or BP in case it is invited in official compendium other than IP.	Bidder may submit the bid with licence issued in any of the compendium if drug is invited in official compendium other than IP.
---	-----------------------------------	--	---

### **Annexure- B: -**

#### **Part- A**

Sl. No.	Tender Clause/ Reference	Drug Code with Generic Name of the Drug	Composition of the Drug in tender	Query/Request	Amendment
1	Annexure - XII Clause 18 (M) & BOQ	DC 1850; Thyroxine Sodium IP Tablets 12.5 mcg	Each Uncoated tablet Contains: Thyroxine Sodium IP Equivalent to anhydrous Thyroxine Sodium 12.5 mcg	Bidder has requested to accept one year old MMC and production certificate	Tender requirement prevails.
2	Annexure - XII Clause 18 (M) & BOQ	DC 1853; Thyroxine Sodium IP Tablets 125 mcg	Each Uncoated tablet Contains: Thyroxine Sodium IP Equivalent to anhydrous Thyroxine Sodium 125 mcg	Bidder has requested to accept one year old MMC and production certificate	Tender requirement prevails.
3	Annexure - XII Clause 18 (M) & BOQ	DC 1856; Disodium Hydrogen Citrate (1.53 gm/5ml) BP Syrup	Each 5 ml contains: Disodium Hydrogen Citrate BP 1.53 gm	Bidder has requested to amend strength of Disodium Hydrogen Citrate to 1.40 gm	Tender requirement prevails.
4	Annexure - XII Clause 18 (M) & BOQ	DC 1859; Disodium Hydrogen Citrate (1.37 gm/5ml) IP Syrup	Each 5 ml contains: Disodium Hydrogen Citrate IP 1.37 gm	Bidder has requested to amend strength of Disodium Hydrogen Citrate to 1.20 gm	Tender requirement prevails.
5	Annexure - XII Clause 18 (M) & BOQ	DC 1860; Dutasteride Capsule IP 0.5 mg	Each Soft Gelatin Capsule Contains: Dutasteride IP 0.5 mg	Bidder has requested to amend pack size from 10 X 10 to 10 X 1 X 10 i.e., a blister pack of 10 capsule in mono carton with leaflet and 10 such pack in outer carton.	Tender requirement prevails.
6	Annexure - XII Clause 18 (M) & BOQ	DC 1865, DC 1866, DC 1867 and DC 1868	Specification as per tender document.	Bidder has requested to accept tablet form against DC 1865, DC 1866, DC 1867 and DC1868	Tender requirement prevails.
7	Annexure - XII Clause 18 (M) & BOQ	<b>DC 1958;</b> Risperidone Tablets USP 2 mg	Each Film Coated Tablet Contains: Risperidone USP 2 mg	Bidder has requested to amend reference official compendium “USP” in the product specification offering the same product in “BP”.	The product may be accepted either in USP/BP.

8	Annexure - XII Clause 18 (M) & BOQ	DC 1959; Eicosapentaenoic Acid 180mg and Docosahexaenoic Acid 120mg Soft Gelatin Capsule	Each Soft Gelatin Capsule Contains: Fish Lipid oil equivalent to Eicosapentaenoic Acid 180mg Docosahexaenoic Acid 120mg	Bidder has requested to amend unit size from 30's bottle to 3 X 10capsules blister pack.	Tender requirement prevails.
9	Annexure - XII Clause 18 (M) & BOQ	DC 1961; Methylcobalamine 1500mcg Tablet	Each uncoated Sublingual Tablet contains: Methylcobalamine 1500 mcg	Bidder has requested to amend the dosage form from sublingual tablet to orally disintegrating strips.  Another bidder has offered the product in film coated form.	Tender requirement prevails.
10	Annexure - XII Clause 18 (M) & BOQ	DC 1962; Methylcobalamine 500mcg Tablet	Each uncoated Sublingual Tablet contains: Methylcobalamine 500 mcg	Bidder has offered the product in film coated form.	Tender requirement prevails.
11	Annexure - XII Clause 18 (M) & BOQ	DC 1971; Amoxycillin 200 mg, Clavulanic Acid 28.5mg And Lactic Acid Bacillus 60 Million Spore Dry syrup	Each 5ml Unconstituted Suspension Contains: Amoxycillin Trihydrate IP equivalent to Anhydrous Amoxycillin 200mg Potassium Clavulanate equivalent to Clavulanic Acid 28.5mg Lactic Acid Bacillus 60 Million Spore	Bidder has requested to remove Lactic Acid Bacillus 60 Million Spore from the specification.	Tender requirement prevails with slight modification in term "Each 5ml Unconstituted Suspension Contains:". It shall be read as under: -  Each 5ml Re-constituted Suspension Contains:
12	Annexure - XII Clause 18 (M) & BOQ	DC 1972; Amoxycillin 500mg, Clavulanic Acid 125mg and Lactic Acid Bacillus 60 mg Tablets	Each film coated tablet contains Amoxycillin Trihydrate IP Equivalent to Amoxicillin 500 mg Potassium Clavulanate Diluted IP Equivalent to Clavulanic acid 125 mg Lactic Acid Bacillus-60 million spores	Bidder has requested to remove Lactic Acid Bacillus 60 Million Spore from the specification.	Tender requirement prevails.
13	Annexure - XII Clause 18 (M) & BOQ	DC 1973; Amoxycillin 200 mg, Clavulanic Acid 28.5mg And Lactic Acid Bacillus 30 Million Spore Dry syrup	Each 5ml Unconstituted Suspension Contains: Amoxycillin Trihydrate IP equivalent to Anhydrous Amoxycillin 200mg Potassium Clavulanate equivalent to Clavulanic Acid 28.5mg Lactic Acid Bacillus 30 Million Spore	Bidder has requested to remove Lactic Acid Bacillus 30 Million Spore from the specification.	Tender requirement prevails with slight modification in term "Each 5ml Unconstituted Suspension Contains:" It shall be read as under: -  Each 5ml Re-constituted Suspension Contains:

14	Annexure - XII Clause 18 (M) & BOQ	DC 1981; Cefixime 50mg and Clavulanic Acid 125mg Dry Syrup	Each 5ml Suspension contains Cefixime Trihydrate IP Equivalent to Anhydrous Cefixime 50 mg Potassium Clavulanate equivalent to Clavulanic Acid 125mg	Bidder has requested to amend strength of Potassium Clavulanate from 125mg to 31.25mg	The following Amendment is hereby authorized as below: - DC 1981; Cefixime 50mg and Clavulanic Acid 31.25 mg Dry Syrup <b>Composition:</b> Each 5ml Suspension contains Cefixime Trihydrate IP Equivalent to Anhydrous Cefixime 50 mg Potassium Clavulanate equivalent to Clavulanic Acid 31.25mg
15	Annexure - XII Clause 18 (M) & BOQ	DC 1982; Cefixime 100mg and Clavulanic Acid 62.5 Mg Tablets	Each Film coated tablet contains Cefixime Trihydrate IP Equivalent to Anhydrous Cefixime 100 mg Potassium Clavulanate equivalent to Clavulanic Acid 62.5mg	Bidder has requested to accept the product in 6's unit size.	Tender condition prevails.
16	Annexure - XII Clause 18 (M) & BOQ	DC 1989; Ceftazidime 250 mg and Tazobactam 51.25 mg Injection	Each Vial contains: Ceftazidime IP Equivalent to Anhydrous Ceftazidime IP 250mg Tazobactam Sodium equivalent to Tazobactam IP 51.25 mg	Bidder has requested to amend strength of Tazobactam IP 51.25 mg to 31.25mg	The following Amendment is hereby authorized as below: - DC 1989; Ceftazidime 250mg and Tazobactam 51.25 mg Injection  <b>Each Vial contains:</b> Ceftazidime IP Equivalent to Anhydrous Ceftazidime IP 250mg Tazobactam Sodium equivalent to Tazobactam IP 31.25 mg
17	Annexure - XII Clause 18 (M) & BOQ	DC 1996; Aceclofenac 100mg, Paracetamol 325mg and Trypsin-Chymotrypsin 150000AU Tablets	Each Tablet Contains: Aceclofenac 100mg, Paracetamol 325mg Trypsin-Chymotrypsin 150000AU	Bidder has requested to amend strength of Trypsin-Chymotrypsin from 150000AU to 50000AU	Tender requirement prevails.
18	Annexure - XII Clause 18 (M) & BOQ	DC 1998 (Carboprost 250 mcg Injection) and DC 1999 (Carboprost 125 mcg Injection)	Specification as per tender document.	Bidder has requested to amend the unit pack to both 1ml Ampoule/vial and 0.5ml Ampoule/vial, respectively.	The product may be accepted in any of the packing.

19	Annexure - XII Clause 18 (M) & BOQ	<b>DC 2000;</b> Dinoprostone 0.5 mg Gel	Each tube contains: Dinoprostone 0.5 Mg in a suitable base	Bidder has requested to amend the unit size	The following Amendment is hereby authorized in unit size as below: -  “3 gm Pre-Filled Syringe”.
20	Annexure - XII Clause 18 (M) & BOQ	DC 2019; Glimepiride 3 mg and Metformin Hydrochloride 1000 mg Sustained Release Tablets	Each Film coated Tablet contains: Glimepiride 3 mg Metformin Hydrochloride 1000 mg	Bidder has requested to accept the product in 15's unit size.	Tender condition prevails.
21	Annexure - XII Clause 18 (M) & BOQ	DC 2037; Esomeprazole IP 20mg Gastro-Resistance Tablets	Each Gastro-Resistance Tablet contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole 20mg Tablet	Bidder has requested to amend the dosage form from Tablet to capsule.	Tender condition prevails.
22	Annexure - XII Clause 18 (M) & BOQ	DC 2047; Cholecalciferol 60000 IU Soft Gelatin Capsule	Each Soft Gelatin Capsule contains: Cholecalciferol (Vitamin D3) IP 60000 IU	Bidder has requested to amend pack size from 4's X 10 to 4's X 1 X 10 i.e., a blister pack of 4 capsule in mono carton and 10 such pack in outer carton.  whereas another bidder has requested to amend the dosage form offering orally disintegrating strips.	The following Amendment is hereby authorized as below: -  Pack size 4's X 1 X 10 i.e., a pack of 4 capsule in mono carton and 10 such pack in outer carton.  Tender condition prevails.
23	Annexure - XII Clause 18 (M) & BOQ	DC 2054; Mecobalamin 1500 mcg + Alpha Lipoic Acid 100mg + Inositol 100mg +Folic Acid 1.5mg + Chromium Picolinate 200Mcg + Selenium Dioxide 55mcg + Benfotiamine 15mg Tablets	Each film coated tablets contains: Mecobalamin IP 1500mcg Alfa Lipoic Acid 100mg Inositol 100mg Folic Acid IP 1.5mg Chromium Picolinate 200mcg Selenium Dioxide 55mcg Benfotiamine 150mg	Bidder has requested to amend the dosage form from Tablet to capsule.	Tender requirement prevails.

**Part-B**

The following drugs/medicines is hereby deleted from the Annexure- XII, Annexure XIV of the tender document and BOQ. Details are as below: -

<b>Sl. No.</b>	<b>Drug Code</b>	<b>Generic name of the drug</b>	<b>Unit Size</b>
1	1998	Carboprost 250 mcg Injection	1ml Ampoule
2	2042	Clonazepam 0.25mg Mouth Dissolving Tablets	10's

**All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment no. 1 dated 07/04/2021.**

Sd/-  
Manager (Procurement)  
For & on behalf of BPPI  
Ph: 011-49431812